Pharmaceuticals, Biotechnology and Life Sciences
Novartis has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries.
European Commission has approved Switzerland-based Novartis’ Entresto tablets for treating adult patients with symptomatic chronic heart failure with reduced ejection fraction.
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.
Novartis’ division and eye care specialist Alcon, is introducing its latest advancement in its WaveLightrefractive portfolio Contoura Vision.
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…
Novartis has announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer.
Novartis has announced new late-breaking data demonstrating that Cosentyx (secukinumab) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.
Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya (fingolimod).